Synchronous development of HCC and CCC in the same subsegment of the liver in a patient with type C liver cirrhosis

Table 1 Clinical status of reported cases of synchronous double cancer with hepatocellular carcinoma and cholangiocellular carcinoma

Clinical status	Compiled numbers
Age, in years (mean ± SD) (range)	66.7 ± 7.4 (51-84) (y/o)
Sex	Total: 33
Male	30 (90.9%)
Female	3 (9.1%)
Anti-HCV	Total: 33
Positive	24 (72.7%)
Negative	9 (27.3%)
HBs antigen	Total: 33
Positive	3 (9.1%)
Negative	30 (90.9%)
	Total: 33
Neither HBV nor HCV infection	2 (6.1%)
	Total: 33
Both positive HBV and HCV infections	1 (3.0%)
Tumor markers	The number/Total number
High levels of CEA (> 3.0 ng/mL)	11/24 (45.8%)
High levels of CA19-9 (> 37 ng/mL)	12/21 (57.1%)
High levels of AFP (> 10 ng/mL)	25/33 (75.8%)
Localization of HCCs and CCCs	Total: 33
In the same subsegment	3 (9.1%)
In the segment of the liver accessed by the same portal vein	5 (15.2%)
In a segment of the liver accessed by a different portal vein-	22 (66.7%)
Mean maximum size of the tumors (mean ± SD) (range)	Total: 33
HCC	3.9 ± 2.7 (0.8-10.0) (cm)
CCC	3.3 ± 3.0 (0.6-14.0) (cm)
Pathological diagnosis of the non-cancerous portions of the liver	Total: 33
Chronic hepatitis	19 (57.6%)
Liver cirrhosis	12 (36.4%)
Therapeutic procedures	Total: 33
Surgery	24 (72.8%)
TAE	2 (6.1%)
Hepatic arterial infusion therapy	1 (3.0%)
Surgery plus PEIT	1 (3.0%)
Surgery plus MCT	1 (3.0%)
Liver transplantation	1 (3.0%)
Unknown	3 (9.1%)

y/o: Years old; HCV: Hepatitis C virus; HB(V): Hepatitis B (virus); CEA: Carcinoembryonic antigen; AFP: α fetoprotein; HCC: Hepatocellular carcinoma; CCC: Cholangiocellular carcinoma; TAE: Transcatheter arterial embolization; PEIT: Percutaneous ethanol injection therapy; MCT: Microwave coagulation therapy.